HTG Molecular Diagnostics (HTGM) Receives Coverage Optimism Rating of 0.14

News articles about HTG Molecular Diagnostics (NASDAQ:HTGM) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.981297786938 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Shares of HTGM traded up $0.15 during mid-day trading on Monday, reaching $3.51. The company had a trading volume of 170,509 shares, compared to its average volume of 1,983,865. HTG Molecular Diagnostics has a twelve month low of $1.59 and a twelve month high of $7.68. The stock has a market cap of $95.28, a PE ratio of -1.94 and a beta of 1.63.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Thursday, March 22nd. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.15. The company had revenue of $7.90 million during the quarter, compared to analyst estimates of $7.05 million. analysts anticipate that HTG Molecular Diagnostics will post -0.67 earnings per share for the current fiscal year.

Several equities analysts have commented on HTGM shares. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the company a “buy” rating in a report on Wednesday, December 27th. Zacks Investment Research cut HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Finally, Canaccord Genuity increased their target price on HTG Molecular Diagnostics to $5.00 in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.56.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3343549/htg-molecular-diagnostics-htgm-receives-coverage-optimism-rating-of-0-14.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Insider Buying and Selling by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Positive Press Coverage Somewhat Unlikely to Affect GoPro  Stock Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect GoPro Stock Price
BlackRock Enhanced Capital And Income Fund  Earning Favorable Media Coverage, Study Finds
BlackRock Enhanced Capital And Income Fund Earning Favorable Media Coverage, Study Finds
Voya Prime Rate Trust  Earns Media Impact Score of 0.21
Voya Prime Rate Trust Earns Media Impact Score of 0.21
Female Health  Upgraded to “Hold” by Zacks Investment Research
Female Health Upgraded to “Hold” by Zacks Investment Research
TrustCo Bank  Lowered to Hold at BidaskClub
TrustCo Bank Lowered to Hold at BidaskClub
Bitcoin Trading 9.9% Higher  This Week
Bitcoin Trading 9.9% Higher This Week


Leave a Reply

© 2006-2018 Ticker Report. Google+.